Results 141 to 150 of about 2,427 (179)

Drug Interactions between Androgen Receptor Axis-Targeted Therapies and Antithrombotic Therapies in Prostate Cancer: Delphi Consensus. [PDF]

Cancers (Basel)
Leblanc K, Edwards SJ, Dranitsaris G, Leong DP, Carrier M, Malone S, Rendon RA, Bond AM, Sitland TD, Zalewski P, Wang M, Emmenegger U.   +11 more
europepmc   +1 more source

Addressing cardiovascular risks with a goal to prevent cardiovascular complications in patients undergoing antihormonal therapy for prostate cancer. [PDF]

Cardiooncology
Shah NP, Singh A, Higano T, Tilki D, Fleshner N, Nguyen P, Plummer C, Rivas JG, Zhang K, Rendon R, Morgans A, Cirne F, Leong D, Lenihan D, Lopes RD.   +14 more
europepmc   +1 more source

The impact of robotic surgery access on the management of patients with clinical stage I kidney tumors. [PDF]

Can Urol Assoc J
Lemire F, Zhang M, Anderson P, Finelli A, Rendon RA, Tanguay S, Bansal R, Bhindi B, So AI, Pouliot F, Dean L, Mallick R, Lavallée LT, Breau RH.   +13 more
europepmc   +1 more source

Addressing controversial areas in the management of advanced prostate cancer in Canada Areas of consensus and controversy from the third Canadian consensus forum. [PDF]

Can Urol Assoc J
Saad F, Hotte SJ, Noonan K, Malone S, Morash C, Niazi T, Rendon RA, Shayegan B, Basappa NS, Cagiannos I, Danielson B, Delouya G, Fernandes R, Ferrario C, Finelli A, Gotto GT, Hamilton RJ, Izard JP, Kapoor A, Lalani AK, Lavallée LT, Ong M, Pouliot F, So AI, Yip S, Chi KN.   +25 more
europepmc   +1 more source

Podium Session 3: Oncology - Bladder, Kidney, Testes Sunday, June 30, 2024 • 13:20-14:20. [PDF]

Can Urol Assoc J
europepmc   +1 more source